Johnson & Johnson: Good & Bad News
Johnson & Johnson stock has edged lower on mixed news about its drug products.
10:47AM 11/30/09
Biotech Calendar: Key Dates for December
A calendar of important, potentially stock-moving biotech events for December.
09:56AM 11/30/09
Eli Lilly's Cymbalta Gets Additional FDA Approval
Eli Lilly's Cymbalta gets FDA approval as a maintenance drug for generalized anxiety disorder
08:18AM 11/30/09
FDA Approves Cymbalta(R) For Maintenance Treatment Of Generalized Anxiety Disorder
08:00AM 11/30/09
Jim Cramer's Best Blogs (RealMoney.com $)
Catch up on Jim Cramer's thinking on the hottest topics of the past week.
08:54AM 11/28/09
Sanofi Has Lots of Upside Catalysts (RealMoney.com $)
Looks like the patent worries aren't so dire after all.
08:12AM 11/23/09
Moody's Gives Negative View On Pharma Credit
Moody's: credit ratings for drugmakers could be hurt as industry copes with expiring patents
01:15PM 11/19/09
Ex-pharma Executive Runs As Dem For Kan. Governor
Former pharmaceutical executive forms to run as Democrat for Kansas governor
11:33AM 11/18/09
Another Genzyme Drug Goes Kaboom: BioBuzz
Company halts development of kidney disease drug following poor test results.
08:05AM 11/18/09
Vivus Seeks Faster ED Drug: Biobuzz
Company says ED drug met all goals in phase III study.
06:42AM 11/18/09
Practicing Balance With P&G: China Watch
By Brittany Umar | By Stephanie Link
NEW YORK -- Stephanie Link, director of research for Action Alerts PLUS, explains why she is still such a fan of Procter & Gamble and why this stock could be a perfect balance for your China portfolio.
05:00AM 11/09/09
Stock Picks for the Defensive Investor (RealMoney.com $)
In light of investor wariness, here are a few stocks that fit Graham's defensive approach.
02:30PM 11/03/09
Evan Bayh: Hypocrisy on the Public Option
Sen. Evan Bayh's wife Susan (left) sits on the board of WellPoint. She and the company stand to benefit if the public option on health care fails.
06:45AM 10/29/09
Evan Bayh: Hypocrisy on the Public Option (RealMoney.com $)
The senator's wife sits on the board of WellPoint, which will benefit if the public option fails.
03:57PM 10/28/09



Connect with TheStreet